Antares Pharma (ATRS) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Antares Pharma Reports First Quarter 2015 Operating and Financial Results
May 11, 2015 7:00 AM EDTEWING, N.J., May 11, 2015 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (Nasdaq: ATRS) today reported operating and financial results for the first quarter ended March 31, 2015. The Company reported revenue of $8.3 million and net loss per share of $0.05. Antares ended the first quarter with $26.5 million in cash and investments and no debt.
Recent Developments and First Quarter 2015 Highlights
Priced a firm commitment underwritten public offering of 23,000,000 shares of the Company's common stock, which includes 3,000,000 shares pursuant to the underwriters' exercise of their option in full, at a purchase... MoreAntares Pharma Reports First Quarter 2015 Operating and Financial Results
May 11, 2015 7:00 AM EDTEWING, N.J., May 11, 2015 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (Nasdaq: ATRS) today reported operating and financial results for the first quarter ended March 31, 2015. The Company reported revenue of $8.3 million and net loss per share of $0.05. Antares ended the first quarter with $26.5 million in cash and investments and no debt.
Recent Developments and First Quarter 2015 Highlights
Priced a firm commitment underwritten public offering of 23,000,000 shares of the Company's common stock, which includes 3,000,000 shares pursuant to the underwriters' exercise of their option in full, at a purchase... More